About Enzymatics
Enzymatics is a Healthcare company based in Beverly (United States) founded in 2006 by Stephen Picone and Christopher Benoit, and was acquired by Qiagen in January 2015. Enzymes and DNA kits for next-generation sequencing are manufactured. Enzymatics has raised $3.79 million across 2 funding rounds from investors including Qiagen. The company has 140 employees. Enzymatics offers products and services including QuantiNova DNA Polymerase, Taq-B DNA Polymerase, T4 DNA Ligase, and Reverse Transcriptases. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its competitors include Neogen, GenScript and RareCyte; 3 of its 3 listed competitors have raised funding.
Company details
Enzymatics was founded in 2006 and is based in Beverly, United States. Enzymes and DNA sample preparation kits for next-generation sequencing are produced by the company within the biotechnology sector. Custom reagents or formulations are developed to address specific customer needs. Kits compatible with Illumina and Ion Torrent platforms are supplied for NGS applications. Operations focus on reagent manufacturing and tailored solutions for sequencing workflows.
- Headquarters Beverly, United States
- Employees 140
- Founders Stephen Picone, Christopher Benoit
- Stage Acquired
- SectorsHealthcare
- Website enzymatics.com
- Social LinkedIn X
- Acquired by Qiagen (Jan 2015)
Products & Services of Enzymatics
Enzymatics offers a comprehensive portfolio of products and services, including QuantiNova DNA Polymerase, Taq-B DNA Polymerase, T4 DNA Ligase, and Reverse Transcriptases.
Enzyme for qPCR and multiplex PCR applications in molecular biology.
Used for standard PCR and DNA amplification reactions.
Facilitates DNA cloning and library preparation processes.
Enables cDNA synthesis for RT-PCR and RNA analysis.
Funding Insights of Enzymatics
Enzymatics has successfully raised a total of $3.79M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.79 million completed in August 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.79M
- Total Rounds 2
- Last Round Series A β $3.79M
- First Round $1.6M
(Sep 2006)
All 2 funding rounds of Enzymatics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2013 | $3.79M | Series A | β | β | β |
| Sep 2006 | $1.6M | Debt – Convertible | β | β | β |
1 investors in total: 1 institutional.
Investors in Enzymatics
Enzymatics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Qiagen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for Enzymatics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enzymatics
2 people are tracked at Enzymatics (2 in leadership); the tracked headcount is 140.
| Name | Role | Group |
|---|---|---|
Stephen Picone | Co-Founder & CSO | Leadership |
Christopher Benoit | Co-Founder & COO | Leadership |
Complete people profiles for Enzymatics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Enzymatics
4 dated milestones of Enzymatics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Enzymatics is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Series A, of $3.8M.
- Exit Acquired by Qiagen.
Competitors of Enzymatics
Enzymatics has 3 listed competitors in our database, 3 of them funded. They include Neogen, GenScript and RareCyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood |
Detailed competitors of Enzymatics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Enzymatics
Websites that share an audience with Enzymatics (enzymatics.com).
Websites whose visitors overlap most with Enzymatics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lucigen.com | 100% | View details | |||
| epibio.com | 92% | View details | |||
| mclab.com | 78% | #2,661,746 | View details | ||
| biotools.eu | 77% | 1.7K | #10,511,342 | View details | |
| bioron.net | 75% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 10 similar websites and full traffic analytics for Enzymatics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Enzymatics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Enzymatics
Enzymatics was founded in 2006.
Enzymatics is headquartered in Beverly, United States. It is registered at Beverly, Massachusetts, United States.
Enzymatics is a funded company, having raised a total of $3.79M across 2 funding rounds to date. The company's 1st funding round was a Debt β Convertible of $1.6M, raised on Sep 2006.
Enzymatics has 140 employees.
Enzymatics was founded in 2006 and is based in Beverly, United States. Enzymes and DNA sample preparation kits for next-generation sequencing are produced by the company within the biotechnology sector. Custom reagents or formulations are developed to address specific customer needs. Kits compatible with Illumina and Ion Torrent platforms are supplied for NGS applications. Operations focus on reagent manufacturing and tailored solutions for sequencing workflows.
Enzymatics offers QuantiNova DNA Polymerase, Taq-B DNA Polymerase, T4 DNA Ligase, and Reverse Transcriptases.
Enzymatics has 1 investor. Key investors include Qiagen.
Yes. Enzymatics was acquired by Qiagen in January 2015.
